CellCentric Partner
CellCentric is a biotechnology company founded in 2004 by Prof. Azim Surani, an expert in cell fate control research. The company is dedicated to developing innovative treatments for specific cancers, particularly multiple myeloma, by targeting the p300/CBP protein involved in cancer progression.
The company's mission is to improve outcomes for patients with specific cancers by quickly advancing effective treatments. CellCentric focuses on identifying novel targets and mechanisms in cancer treatment, collaborating with leading research centers, and engaging with patients to understand their needs. Its primary product in development is inobrodib, an oral drug that inhibits p300/CBP and is currently undergoing clinical trials. Through its research and development efforts, CellCentric aims to make a significant impact in the field of cancer treatment.
